Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates
- Collegium Pharmaceutical reported earnings of $1.45 per share, missing estimates. - Revenue for the quarter was $144.92 million, slightly below expectations. - Stock performance has outpaced the S&P 500, gaining 23.7%. - Earnings outlook is mixed, with a Zacks Rank #3 (Hold). - Industry rank for Medical - Drugs is in the top 40%. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysis